[Current Cancer Immunotherapy Using Activated Lymphocytes - Do Lymphocytes Actually Recognize Cancer Cells ?]

Area of Science:

• Immunotherapy
• Cellular Therapy
• Regenerative Medicine

Context:

• Interleukin-2 (IL-2) molecular cloning enables adoptive cell therapy (ACT) using autologous activated lymphocytes.
• Regenerative medicine advancements are driving the development of ACT for public use.
• Several ACT types, including tumor-infiltrating lymphocytes (TIL), are evaluated as advanced medical treatments in Japan.

Purpose:

• To review the current landscape and future directions of adoptive cell therapy (ACT) in cancer treatment.
• To highlight the potential and challenges of advanced cell-based therapies.
• To emphasize the critical role of antigen selection in gene-modified T cell therapies.

Summary:

• Molecular cloning of IL-2 has facilitated ACT development using autologous lymphocytes.
• Investigational therapies include TIL, in vitro tumor-sensitized lymphocytes, NK T cells, gammadelta T cells, CAR-T, and TCR-T cells.
• CAR-T and TCR-T cells demonstrate significant efficacy alongside serious adverse events, underscoring the importance of target antigen selection.
• Lymphocytes recognize cancer cells, paving the way for future personalized immunotherapies.

Impact:

• ACT, particularly gene-modified T cell therapies, offers potent anti-cancer potential.
• The development of personalized immunotherapy based on TIL and cancer-specific antigens is anticipated.
• Careful consideration of target antigens is crucial for optimizing the risk-benefit profile of advanced ACTs.